Oncorus (OTCPK:ONCR) - Stock Price, News & Analysis

Resumen acción ONCR

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients.

Acerca de la empresa

ONCR fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Recompensas

Análisis de riesgos

Los beneficios han disminuido en 25.8% al año en los últimos 5 años.

No tiene una capitalización bursátil significativa ($287K)

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Alta volatilidad del precio de la acción en los últimos 3 meses

+ 1 riesgos adicionales

Competidores de Oncorus, Inc.

Finch Therapeutics Group

NasdaqGS:FNCH

US$3.3m

Aptevo Therapeutics

NasdaqCM:APVO

US$3.3m

Atreca

OTCPK:BCEL

US$3.2m

Revelation Biosciences

NasdaqCM:REVB

US$3.4m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Oncorus
Historical stock prices
Current Share Price	US$0.13
52 Week High	US$0.47
52 Week Low	US$0.01
Beta	1.95
1 Month Change	500.00%
3 Month Change	427.20%
1 Year Change	-58.00%
3 Year Change	-99.63%
5 Year Change	n/a
Change since IPO	-99.21%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	ONCR	US Biotechs	Mercado US
7D	26.0%	-2.9%	-1.7%
1Y	-58.0%	-0.2%	22.9%

Rentabilidad vs. Industria: ONCR obtuvo unos resultados inferiores a los del sector US Biotechs , que el año pasado arrojó un rendimiento del -3.5%.

Rentabilidad vs. Mercado: ONCR obtuvo unos resultados inferiores a los del mercado US, que fue del 15.2% el año pasado.

Volatilidad de los precios

Is ONCR's price volatile compared to industry and market?
ONCR volatility
ONCR Average Weekly Movement	210.0%
Biotechs Industry Average Movement	11.6%
Market Average Movement	6.1%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: ONCRha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: ONCRLa volatilidad semanal ha pasado de 31% a 43% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2015	64	Craig Jalbert	www.oncorus.com

Resumen de fundamentos de Oncorus, Inc.

¿Cómo se comparan los beneficios e ingresos de Oncorus con su capitalización de mercado?
Estadísticas fundamentales de ONCR
Capitalización bursátil	US$3.29m
Beneficios(TTM)	-US$90.54m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

0.0x

Ratio precio-beneficio (PE)

¿Está ONCR sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ONCR
Ingresos	US$0
Coste de los ingresos	US$0
Beneficio bruto	US$0
Otros gastos	US$90.54m
Beneficios	-US$90.54m

Últimos beneficios comunicados

Mar 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-3.47
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	66.0%

¿Cómo se ha desempeñado ONCR a largo plazo?

Ver rendimiento histórico y comparativa

Resumen acción ONCR

Recompensas

Análisis de riesgos

Competidores de Oncorus, Inc.

NasdaqGS:FNCH

US$3.3m

NasdaqCM:APVO

US$3.3m

OTCPK:BCEL

US$3.2m

NasdaqCM:REVB

US$3.4m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Oncorus, Inc. Files Form 15

Nasdaq to Delist the Common Stock of Oncorus

Oncorus, Inc.(OTCPK:ONCR) dropped from S&P TMI Index

Oncorus Receives Written Notice from The Nasdaq Stock Market LLC Regarding in Light of the Plan of Dissolution

Oncorus Announces Management Changes

Oncorus, Inc. Announces Workforce Reduction Plan

Recent updates

Oncorus, Inc. Files Form 15

Nasdaq to Delist the Common Stock of Oncorus

Oncorus, Inc.(OTCPK:ONCR) dropped from S&P TMI Index

Oncorus Receives Written Notice from The Nasdaq Stock Market LLC Regarding in Light of the Plan of Dissolution

Oncorus Announces Management Changes

Oncorus, Inc. Announces Workforce Reduction Plan

Oncorus, Inc. Appoints Alexander Nolte as Principal Accounting Officer

Oncorus, Inc. announced delayed 10-Q filing

Nasdaq Grants Oncorus an Additional 180 Calendar Days, or Until October 30, 2023, to Regain Compliance with the Minimum Closing Bid Price

Oncorus, Inc. Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

Oncorus, Inc. Announces the Presentation of Preclinical Data for ONCR-719 in A Poster At the 2022 Society for Neuro-Oncology Annual Meeting

Price target decreased to US$5.75

Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer

Now 23% undervalued

Oncorus GAAP EPS of -$0.74 misses by $0.02

Oncorus, Inc. Appoints Douglas Fambrough to Board of Directors

Oncorus, Inc., Annual General Meeting, Jun 22, 2022

Oncorus, Inc. Announces the Appointment of Richard Wanstall as Chief Financial Officer

Price target decreased to US$17.00

Oncorus, Inc. Presents Preclinical Data on ONCR-021 and ONCR-788 Supporting Selectively Self-Amplifying vRNA Immunotherapy Platform at AACR Annual Meeting

Oncorus, Inc. announced that it expects to receive $45 million in funding from K2 HealthVentures

Oncorus, Inc. Promotes John Goldberg to Chief Medical Officer

President exercised options to buy US$184k worth of stock.

COO & Chief of Staff recently bought US$174k worth of stock

Price target decreased to US$34.75

President exercised options to buy US$469k worth of stock.

We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

Oncorus: Shares Look Cheap As First Oncolytic Viral Therapy Enters Clinic

Oncorus, Inc.(NasdaqGM:ONCR) dropped from Russell 3000E Growth Index

Independent Director Robert Kirkman has left the company

Independent Director Cameron Wheeler has left the company

Oncorus Announces Nomination of its First IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Product Candidates, ONCR-021 and ONCR-788

Insider exercised options to buy US$590k worth of stock.

Oncorus (NASDAQ:ONCR) Is In A Good Position To Deliver On Growth Plans

Independent Director has left the company

Oncorus Anticipates Reporting Interim Data from its Ongoing Phase 1 Clinical Trial of its Lead oHSV-Based Clinical Candidate ONCR-177 in Patients with Solid Tumor Indications in the Second Half of 2021

What Kind Of Shareholders Own Oncorus, Inc. (NASDAQ:ONCR)?

New 90-day low: US$20.97

Oncorus: Buy On A Dip, Potential Already Priced In At Current Levels

Oncorus, Inc. Announces Publication of Preclinical Data Demonstrating Potent Systemic Antitumor Activity of its Clinical Stage Oncolytic Herpes Simplex Viral Immunotherapy Product Candidate ONCR-177

New 90-day high: US$35.55

Oncorus to build viral immunotherapy clinical manufacturing facility in U.S.

We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

Oncorus Appoints Scott Canute to Its Board of Directors

Oncorus reports Q3 results

Oncorus, Inc. has filed an IPO in the amount of $86.25 million.

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Oncorus, Inc.

0.0x

0.0x

Beneficios e Ingresos